AI Prompt

Amkor Technology (AMKR) Investment Analysis: Global OSAT riding AI, smartphone, and auto semiconductor demand; accelerating advanced-packaging expansion in Vietnam and the U.S.※ Amkor Technology (NASDAQ: AMKR) is a U.S.-headquartered global OSAT (outsourced semiconductor assembly & test) leader. Leveraging advanced packaging capabilities such as wafer-level, SiP, fan-out, and flip-chip, it targe..

Evoke Pharma (EVOK) Investment Analysis: Targeting diabetic gastroparesis (DGP) with the intranasal metoclopramide “GIMOTI” — acquisition proposal reported in Nov 2025※ Evoke Pharma (NASDAQ: EVOK) is a commercial-stage biotech focused on GIMOTI, an intranasal metoclopramide for symptoms of diabetic gastroparesis (DGP). After a 1-for-12 reverse split in 2024 to address Nasdaq bid-price rules, the..

ProShares UltraPro Short QQQ (SQQQ) Investment Analysis: Daily −3× inverse exposure to the Nasdaq-100 — a leveraged ETF for short-term hedging and tactical trading only※ SQQQ (ProShares UltraPro Short QQQ) is a daily inverse leveraged ETF targeting −3× the daily return of the Nasdaq-100 Index. It charges a 0.95% expense ratio, was launched on 2010-02-09, and uses derivatives (e.g., swaps) to res..

Denny’s (DENN) Investment Analysis: Repositioning a family-diner chain — Keke’s expansion, virtual brands, remodels, and a take-private announced in November 2025※ Denny’s (NASDAQ: DENN) is a leading U.S. family-style diner chain. In 2022 it bolstered its breakfast portfolio by acquiring Keke’s Breakfast Café and has expanded off-premise sales via virtual brands such as The Meltdown, The Burger ..

EZGO Technologies (EZGO) Investment Analysis: China short-distance e-mobility (e-bikes & batteries) + BaaS expansion — a microcap highly sensitive to listing-rule and funding events※ EZGO Technologies (NASDAQ: EZGO) is a China-based small-cap focused on electric bicycles (e-bikes), batteries, and short-distance transportation solutions. The company executed a 1:40 reverse split in 2024, received..

MingZhu Logistics Holdings (YGMZ) Investment Analysis: China-wide 4A-grade trucking network with hybrid fleet model — diversification in a rebuilding phase (watch listing-rule & contract events)※ MingZhu Logistics Holdings (NASDAQ: YGMZ) is a Shenzhen-based 4A-grade trucking/logistics company. By mixing owned and subcontracted trucks, it serves enterprise customers across China with broad covera..

Caribou Biosciences (CRBU) Investment Analysis: Commercializing “off-the-shelf” allogeneic CAR-T via precise CRISPR chRDNA editing — refocusing on CB-010 (lymphoma) & CB-011 (multiple myeloma)※ Caribou Biosciences (NASDAQ: CRBU) is a gene-editing biotech developing allogeneic CAR-T therapies using its CRISPR hybrid guide (chRDNA) technology. Lead programs are CB-010 (anti-CD19 for large B-cell l..

iBio (IBIO) Investment Analysis: AI-driven epitope-steered antibody design targeting obesity, cardiometabolic disease, and oncology — Uplisted to Nasdaq on 2025-03-04 (ticker unchanged)※ iBio (NASDAQ: IBIO) is a computational biology/AI-powered antibody discovery and design company. With its epitope-steered engine and AI platform, it designs antibody candidates for hard-to-drug targets, expandin..

MBX Biosciences (MBX) Investment Analysis: Precision peptide therapy platform for rare endocrine diseases — expansion momentum in hypoparathyroidism and beyond※ MBX Biosciences (NASDAQ: MBX) is a clinical-stage biotech developing precision, peptide-based medicines for rare endocrine disorders. Its core capability is fine control of hormone/peptide axes, with clinical development in hypoparathyro..

MediciNova (MNOV) Investment Analysis: Pipeline targeting neuroinflammation & fibrotic diseases — multi-indication strategy centered on MN-166 (ibudilast) and MN-001 (tipelukast)※ MediciNova (NASDAQ: MNOV) is a clinical-stage biotech focused on neuroinflammation (CNS) and autoimmune/fibrosis. Its key asset MN-166 (ibudilast) targets progressive multiple sclerosis (pMS), ALS, and addiction/pain i..